IMPROVE-IT Wins Statistically but Faces Narrow Label and No Added Value
Clinical Trial Updates

IMPROVE-IT Wins Statistically but Faces Narrow Label and No Added Value

Published : 19 Nov 2026

The Overview
Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints, demonstrating that VYTORIN (ezetimibe/simvastatin) significantly reduced major cardiovascular events compared to simvastatin alone in 18,144 high-risk patients with acute coronary syndromes. At seven years, 32.7% of VYTORIN patients experienced a primary endpoint event versus 34.7% for simvastatin alone (hazard ratio 0.936, p=0.016). This 6.4% relative risk reduction was consistent with projections based on LDL-C lowering, with mean LDL-C levels of 53 mg/dL for VYTORIN versus 70 mg/dL for simvastatin at one year. Merck plans to submit these data to the U.S. FDA in mid-2015 for a new indication.
Knolens Analysis

IMPROVE-IT is the first Phase 3 cardiovascular outcomes success for ezetimibe, with ezetimibe 10 mg plus simvastatin 40 mg reducing major events versus simvastatin 40 mg alone in 18,144 post-acute coronary syndrome patients, 32.7% versus 34.7% at seven years with hazard ratio 0.936 and p equals 0.016 for 6.4% relative risk reduction and mean LDL-C 53 mg/dL versus 70 mg/dL at one year supporting a planned mid-2015 FDA submission for a new indication. [1][2] The effect is modest, heterogeneous and without overall mortality benefit, concentrated in simvastatin pre-treated patients with 2.97% absolute gain, in diabetes with hazard ratio 0.85 versus 0.98 without diabetes, and in age 75 years or older with 20% relative reduction, while low to moderate TIMI-risk non-diabetic patients show no benefit. [3] The resolution precedent is the HAS April 5 2017 EZETROL extension on the same IMPROVE-IT dataset, granting SMR Important only as adjunct to ongoing simvastatin with ASMR V no improvement, 65% reimbursement with prior agreement since June 24 2014 and maximum 13,000 patients per year in France, behind five generic statins with mortality benefit. [1][4] Peers include INEGY identical fixed combination with SHARP n equals 9,438 and 16% relative risk reduction versus placebo, and TWICOR rosuvastatin plus ezetimibe limited to bioequivalence plus small meta-analysis n equals 1,948 with no outcomes claim, while G-BA found no additional benefit for bempedoic acid plus ezetimibe and NICE rejected new split ICERs. [1][4] Regulatory approval as narrow add-on is plausible but broad premium positioning is unsupported, leaving payer segmentation as the binding constraint. [1][4]

IMPROVE-IT Phase 3 RCT n=18,144 met primary HR 0.936 p=0.016 but HAS granted ASMR V with pre-treated-only SMR and no mortality gain.

At a Glance
IndicationAcute Coronary Syndromes
DrugVYTORIN (ezetimibe/simvastatin)
CompanyMerck
Trial AcronymIMPROVE-IT
CategoryClinical Trial Event
Sub CategoryTopline Results Positive
Therapeutic AreaCardiovascular
Primary Endpointmajor cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization)
Patient Populationhigh-risk patients presenting with acute coronary syndromes
Patient Number18,144
Comparatorsimvastatin alone
Hazard Ratio0.936
P-value0.016
Mean LDL-C Levels53 mg/dL (VYTORIN) vs. 70 mg/dL (simvastatin) at one year
Follow-up Durationup to nine years, with a median clinical follow-up of approximately six years
Regulatory Submission PlanU.S. Food and Drug Administration, mid-2015
Conference NameAmerican Heart Association 2014 Scientific Sessions

Merck's VYTORIN Significantly Reduces Cardiovascular Events in IMPROVE-IT Study

Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints, demonstrating that VYTORIN (ezetimibe/simvastatin) significantly reduced major cardiovascular events compared to simvastatin alone in 18,144 high-risk patients with acute coronary syndromes. At seven years, 32.7% of VYTORIN patients experienced a primary endpoint event versus 34.7% for simvastatin alone (hazard ratio 0.936, p=0.016). This 6.4% relative risk reduction was consistent with projections based on LDL-C lowering, with mean LDL-C levels of 53 mg/dL for VYTORIN versus 70 mg/dL for simvastatin at one year. Merck plans to submit these data to the U.S. FDA in mid-2015 for a new indication.

  • The IMPROVE-IT study successfully met its primary composite efficacy endpoint, showing that VYTORIN reduced major cardiovascular events. Specifically, 32.7% of patients on VYTORIN experienced an event compared to 34.7% on simvastatin alone, resulting in a statistically significant hazard ratio of 0.936 (p=0.016) and a 6.4% relative risk reduction. This outcome validates the benefit of further LDL-C lowering in high-risk acute coronary syndrome patients.
  • Beyond the primary endpoint, VYTORIN also achieved significant reductions across all three secondary composite efficacy endpoints. These included composites related to all-cause death, major coronary events, non-fatal stroke; CHD death, non-fatal MI, urgent coronary revascularization; and cardiovascular death, non-fatal MI, documented unstable angina, all revascularization, and non-fatal stroke. These consistent results reinforce the broad cardiovascular benefit of the ezetimibe/simvastatin combination.
  • The study's safety findings were consistent with current ezetimibe labeling, showing no significant differences between treatment groups for adverse events of special interest such as myopathy, rhabdomyolysis, gallbladder events, liver enzyme elevations, or cancer over seven years. Merck intends to submit these comprehensive data to the U.S. Food and Drug Administration in mid-2015 to support a new indication for the reduction of major cardiovascular events for VYTORIN and ZETIA.

Addressing the Persistent Cardiovascular Risk in High-Risk ACS

Dual antiplatelet therapy has been the mainstay of the management of Acute Coronary Syndrome, with clopidogrel therapy providing clear benefits over aspirin monotherapy and becoming the agent of choice for the prevention of stent thrombosis. A central limitation is High Residual Platelet Reactivity (HRPR), with persistent high platelet reactivity consistently associated with recurrence of ischemic events. Clopidogrel metabolism is highly variable, and genetics, comorbidities and drug interactions can affect it. In a cohort of 72 Indian patients stable on dual antiplatelet therapy (clopidogrel 75 mg OD and aspirin 150 mg OD), 51.4% patients had inadequate response to clopidogrel (1.4% resistant and 50% semi-responders), with genotype and allele frequencies of CYP2C192 and PLA1/A2 gene polymorphisms significantly different between clopidogrel semi-responders and responders. Carriers of CYP2C192 and CYP3A53 showed diminished inhibition of platelet aggregation, and CYP2C192 LOF alleles were associated with high risk of MACE in 1-year post PCI operations (OR = 2.571; 95% CI: 1.143-5.780; P = 0.030).

A second challenge is the no-reflow phenomenon, defined as the inability to reperfuse regions of the myocardium after ischemia, despite removal of the large epicardial coronary artery occlusion. The mechanism involves microvascular obstruction, and micro embolization of atherothrombotic debris during PCI remains the principal mechanism responsible for microvascular obstruction. Clinically it manifests with recurrence of chest pain and dyspnea and may progress to cardiogenic shock, cardiac arrest, serious arrhythmias and acute heart failure. No reflow is regarded as independent predictor of death or recurrent myocardial infarction, and patients exhibiting no-reflow following reperfusion therapy for myocardial infarction have greater left ventricular dilation and remodeling, more congestive heart failure, shock, and reduced survival. Certain vasodilators (adenosine, nitroprusside, nicorandil, and calcium blockers) are used acutely in the catheterization laboratory and appear to improve no-reflow, but systematic studies on therapy for no-reflow are needed.

Patients who have experienced a CV event requiring percutaneous coronary intervention (PCI) remain at heightened residual risk for subsequent events, despite advancements in standard-of-care strategies. Growing evidence shows that atherogenic lipids and vascular inflammation drive residual risk after PCI, despite guideline-directed therapy. In secondary prevention, estimates show that 38% of individuals persist with elevated high-sensitivity C-reactive protein and these patients exhibit higher all-cause mortality, myocardial infarction and stroke rates at one year. In the F.I.R.E. trial in 234 patients presenting with acute ST-segment elevation myocardial infarction randomized to FX06 or matching placebo given as intravenous bolus at reperfusion, there was no significant difference in total late gadolinium enhanced zone in the FX06 group compared with placebo (reduction by 21%; p = 0.207), underscoring the difficulty of limiting infarct size by mitigating reperfusion injury.

IMPROVE-IT: Unpacking the Design and Efficacy in ACS

Acute coronary syndrome trials span ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina populations, testing invasive versus conservative management, extent of revascularization, and adjunctive therapies. Designs range from small stratified randomized studies to large multicenter trials, with endpoints including infarct size, microvascular obstruction, major adverse cardiac and cerebrovascular events, mortality, and patient-reported outcomes.

  • TRITON-TIMI 38 substudy of PCI without stent implantation: In TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38, patients (n = 13 608) undergoing PCI for ACS were randomized to aspirin plus clopidogrel or prasugrel, with postrandomization analysis restricted to PCI without stent implantation (n = 569). The composite of cardiovascular death, nonfatal MI, and nonfatal stroke occurred in 14.2% receiving prasugrel and 17.1% receiving clopidogrel (HR 0.82, P = .27), with significant reductions favoring prasugrel in urgent target vessel revascularization (HR 0.46, P = .040) and any target vessel revascularization (HR 0.40, P = .009).

  • TACTICS-TIMI 18 early invasive versus conservative strategy: Randomized controlled trial in 2220 patients with either unstable angina or non-ST-segment elevation myocardial infarction treated with the platelet glycoprotein (Gp IIb/IIIa) inhibitor tirofiban, comparing early invasive strategy with routine catheterization and revascularization as appropriate versus conservative strategy with catheterization only for recurrent ischemia or a positive stress test. Main outcome was total 6-month costs and incremental cost-effectiveness ratio, against a background of significantly reduced rate of major cardiac events at 6 months with early invasive strategy.

  • TATORT-NSTEMI thrombectomy trial: Prospective, controlled, multicenter, randomized, open-label trial enrolling 460 patients randomized 1:1 to adjunctive thrombectomy versus conventional PCI alone against a background of early revascularization. Primary endpoint is extent of late microvascular obstruction assessed by cardiac magnetic resonance imaging, with secondary endpoints of early microvascular obstruction, infarct size, myocardial salvage, enzymatic infarct size, thrombolysis in myocardial infarction flow post-PCI and myocardial blush grade, plus death, myocardial re-infarction, target vessel revascularization, and new congestive heart failure at 6 and 12 months.

  • Octogenarian and After Eighty invasive versus conservative trials: Multicenter, randomized controlled trial planned in 200 patients 80 years of age and over with non-ST elevation myocardial infarction or unstable angina randomized to medical or invasive treatment, with primary outcome of combined endpoint major adverse cardiac or cerebrovascular event (MACCE) within one year. The After Eighty study randomized 457 patients aged 80 or over with NSTEMI or UAP to invasive strategy (n = 229, mean age: 84.7 years) involving early coronary angiography with evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy, or conservative strategy (n = 228, mean age: 84.9 years), with health related quality of life assessed by Short Form 36 at baseline and 1-year follow-up.

  • COMPLETE trial and staged revascularization cohort in STEMI with multivessel disease: The COMPLETE trial randomized 4041 patients with STEMI and multivessel coronary artery disease, including 787 patients (19.5%) with diabetes, to complete revascularization consisting of angiography-guided percutaneous coronary intervention of all suitable nonculprit lesions versus culprit-lesion-only percutaneous coronary intervention, with first coprimary outcome of cardiovascular death or new myocardial infarction and second coprimary outcome of cardiovascular death, new myocardial infarction, or ischemia-driven revascularization. A separate cohort of 371 diabetic patients (staged PCI: 164, culprit-only PCI: 207) and 834 nondiabetic patients (staged PCI: 412, culprit-only PCI: 422) with STEMI and multivessel disease used 5-year major adverse cardiac and cerebrovascular event defined as composite of all-cause death, myocardial infarction, stroke or unplanned revascularization.

  • Late STEMI mechanical reperfusion trial: International, multicenter, open-label, randomized controlled trial in 365 patients aged 18 to 80 years with acute STEMI presenting between 12 and 48 hours after symptom onset without persistent symptoms, randomized to invasive strategy (n=182) based predominantly on coronary stenting with abciximab or conventional conservative strategy (n=183). Primary end point was final left ventricular infarct size by single-photon emission computed tomography with technetium Tc 99m sestamibi between 5 and 10 days after randomization, with secondary end points of composite of death, recurrent MI, or stroke at 30 days.

  • TRACER bleeding validation and secondary prevention trials: Analysis of bleeding in 12,944 patients with acute coronary syndromes without ST-segment elevation, with or without early invasive strategy, with main outcome of all-cause death over median 502 days and comparison of BARC (grades 2, 3, or 5), TIMI minor/major, and GUSTO moderate/severe criteria. A prospective, randomised, single-center study in 260 patients with baseline smoking, BMI ≥25 kg/m, and physical inactivity randomised 1:1 to cardiac rehabilitation or control stratified by STEMI, NSTEMI, and unstable angina pectoris, with primary outcomes of adherence to medical treatment, dietary recommendations, physical activity guidelines, smoking cessation, and weight management at one-year follow-up. A double-blind controlled trial in 93 diabetic patients with ACS who underwent PCI randomized to empagliflozin (10 mg once daily) or placebo for 6 months evaluated all-cause mortality, coronary revascularization, rehospitalization due to unstable angina, hospitalization due to heart failure, cardiovascular death, non-fetal myocardial infarction, and non-fetal stroke during 6 months follow-up.

VYTORIN's Safety Profile in the IMPROVE-IT Trial

Published safety data for ezetimibe/simvastatin show a tolerability profile comparable to statin monotherapy across acute coronary syndrome, type 2 diabetes, and non-alcoholic fatty liver disease populations. In the IMPROVE-IT trial of 18,144 patients with a median follow-up of 6 years, combination therapy showed no excess safety signal over extended exposure, including in patients achieving very low LDL-C levels and in older adults.

  • In acute coronary syndrome, the combined therapy showed no significant adverse effects, particularly regarding the risk of cancers, which confirms the safety of ezetimibe.

  • In a prespecified analysis of 15,281 patients without an event in the first month, after multivariate adjustment, there was no significant association between the achieved LDL-C level and any of the 9 prespecified safety events, which included adverse events leading to drug discontinuation; adverse muscle, hepatobiliary, and neurocognitive events; and hemorrhagic stroke, heart failure, cancer, and noncardiovascular death.

  • Among patients 75 years or older with stabilized acute coronary syndrome, the rate of adverse events did not increase with simvastatin-ezetimibe vs simvastatin-placebo among younger or older patients, and addition of ezetimibe to simvastatin was not associated with any significant increase in safety issues among older patients.

  • Stratified by diabetes mellitus status, no differences in safety outcomes by treatment were present regardless of DM.

  • In patients with type 2 diabetes mellitus and hypercholesterolemia, incidences of clinical adverse events, including serious drug-related and prespecified gastrointestinal-, gallbladder-, and hepatitis-related allergic reactions or rash events, and laboratory adverse events, including repeated elevation of hepatic transaminases or creatine kinase levels, were similar for both treatments, and both treatments were generally well tolerated.

  • In patients with NAFLD associated with type 2 diabetes and metabolic syndrome, both the combined ezetimibe/simvastatin treatment and the simvastatin monotherapy proved to be effective and safe, with ezetimibe/simvastatin treatment resulting in a significant decrease in ALT (63.78+/-5.12 vs 32.57+/-3.92 U/L; p<0.0001) and AST (50.79+/-3.66 vs 23.68+/-3.42 U/L; p<0.0001).

Reshaping the LDL-C Lowering Paradigm for High-Risk ACS

Immediate and aggressive lipid lowering therapies after acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI) are supported by the ESC/EAS dyslipidemia guidelines, recommending the initiation of high-intensity statin therapy within the first 1-4 days of hospitalization. The rationale to explore rapid and aggressive pharmacological intervention with PCSK9 monoclonal antibodies is supported by at least five confirmatory data in ACS: 1) circulating PCSK9 levels are raised during ACS 2) PCSK9 may stimulate platelet reactivity, this last being pivotal in the recurrence of ischemic events; 3) PCSK9 is associated with intraplaque inflammation, macrophage activation and endothelial dysfunction; 4) PCSK9 concentrations are associated with inflammation in the acute phase of ACS; and 5) statins raise PCSK9 levels promptly and, at times, dramatically.

Monoclonal antibodies act on circulating PCSK9 with a direct and rapid binding by blocking the interaction with the low-density lipoprotein receptor (LDLR). Evolocumab and alirocumab show a very rapid (within 4 h) and effective suppression of circulating unbound PCSK9 (- 95 % ÷ - 97 %). This inhibition results in a significant reduction of LDL-cholesterol (LDL-C) after 48 h (- 35 %) post injection with a full effect after 7-10 days (55-75 %). The complete and swift inhibitory action by evolocumab and alirocumab could have a potential clinical impact in ACS patients, also considering their potential inhibition of PCSK9 within the atherosclerotic plaque.

Two major cardiovascular outcome trials showed that the use of the PCSK9 inhibitors (alirocumab and evolocumab) in patients with recent acute coronary syndrome (ACS) is associated with a lower risk of further cardiovascular (CV) events. In a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial in 18 924 patients aged 40 years or older with recent acute coronary syndrome (ie, in the past 1-12 months) and elevated concentrations of atherogenic lipoproteins, despite high-intensity or maximum-tolerated statin treatment, patients were randomly assigned (1:1) to 75 mg alirocumab by subcutaneous injection every 2 weeks or matching placebo, beginning 1-12 months after acute coronary syndrome and were followed up for a median of 2·8 years (IQR 2·3-3·4). In the placebo group, MACE incidence increased monotonically with each metabolic risk factor from 7·8% (no risk factors) to 19·6% (five risk factors; HR 1·18, 95% CI 1·13-1·24 per metabolic risk factor). Alirocumab decreased relative risk of MACE consistently across categories defined by the number of metabolic risk factors (p=0·77), but absolute risk reduction (aRR) increased with the number of metabolic risk factors (no risk factors aRR 0·7%, -1·81 to 3·29 vs five risk factors aRR 3·9%, -1·45 to 9·25; p<0·001). Early evolocumab therapy initiation was associated with a significant decrease in LDL-C levels and was not associated with an increased risk of adverse effects in comparison to placebo, with significant decrease in LDL-C changes from initiation of evolocumab therapy to 8 weeks following ACS compared to placebo and similar results in the sub-acute phase [SMD -1.95 (95% CI -2.29, -1.62)], and no statistically significant relationship between the risk of adverse effects, serious adverse effects, and major adverse cardiovascular events (MACE) from treatment using evolocumab in comparison to placebo [(relative risk, RR 1.04 (95% CI 0.99, 1.08) (Z = 1.53; p=0.12)].

Frequently Asked Questions

Why is aggressive lipid lowering critical in patients with Acute Coronary Syndromes?
Aggressive lipid lowering is paramount in ACS patients to reduce the risk of recurrent cardiovascular events. These patients are at very high risk for subsequent myocardial infarction, stroke, and cardiovascular death due to underlying atherosclerotic disease progression. Intensive reduction of LDL-C stabilizes existing plaques and prevents new plaque formation, thereby improving long-term prognosis.
How does the combination of ezetimibe and simvastatin address lipid targets in post-ACS patients?
Ezetimibe/simvastatin combines two distinct mechanisms to achieve significant LDL-C reduction. Simvastatin, a statin, inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver. Ezetimibe selectively inhibits cholesterol absorption in the small intestine, further lowering circulating LDL-C. This dual action provides complementary pathways for potent lipid modification, often enabling patients to reach guideline-recommended LDL-C goals.
What are the benefits of achieving very low LDL-C levels following an ACS event?
Achieving very low LDL-C levels post-ACS significantly reduces the risk of major adverse cardiovascular events. Intensive lipid lowering has been shown to decrease rates of recurrent myocardial infarction, urgent revascularization, and cardiovascular mortality. This aggressive approach helps to halt or even regress atherosclerotic plaque progression, improving overall cardiovascular health and patient outcomes.
When is combination lipid-lowering therapy considered for secondary prevention after an ACS event?
Combination lipid-lowering therapy is typically considered for secondary prevention after an ACS event when patients do not achieve their individualized LDL-C goals with maximally tolerated statin monotherapy. It is also indicated for very high-risk patients who require substantial LDL-C reduction to meet stringent guideline targets. This approach helps optimize lipid management and further mitigate residual cardiovascular risk.

References

  1. [1] Jimenez JG, Rosen JB et al.. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, obesity & metabolism. 2013 Jun. 23279632
  2. [2] Kammoun R, Charfi O et al.. Statin Associated Muscular Adverse Effects. Current drug safety. 2024. 36847228
  3. [3] Goldberg RB, Guyton JR et al.. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clinic proceedings. 2006 Dec. 17165637
  4. [4] Schömig A, Mehilli J et al.. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005 Jun 15. 15956631
  5. [5] Abel T, Fehér J et al.. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Medical science monitor : international medical journal of experimental and clinical research. 2009 Dec. 19946244
  6. [6] Farnier M, Steinmetz A et al.. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clinical therapeutics. 2011 Jan. 21397769
  7. [7] Godoy LC, Ko DT et al.. The role of coronary artery bypass surgery versus percutaneous intervention in patients with diabetes and coronary artery disease. Progress in cardiovascular diseases. 2019 Jul-Aug. 31377224
  8. [8] Khalil M, Khalil Y. Short- Versus Standard-Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Cureus. 2026 Jun. 42473532
  9. [9] Prasad A, Pratim Datta P et al.. Comparative study of ezetimibe and atorvastatin alone and in combination on lipid profile in rats. Materia socio-medica. 2013. 24167434
  10. [10] Pillai SS, Chaudhry MA et al.. Biomarker Profiling of Cardiac Causes for Chest Pain in Non-acute Coronary Syndrome Patients in West Virginia. Cureus. 2026 Feb. 41743145
  11. [11] Hald K, Larsen FB et al.. Medication adherence, biological and lifestyle risk factors in patients with myocardial infarction: a ten-year follow-up on socially differentiated cardiac rehabilitation. Scandinavian journal of primary health care. 2019 Jun. 31122102
  12. [12] Franco AJ, Krishna MM et al.. Complete versus culprit-only percutaneous coronary intervention in elderly patients with acute coronary syndrome and multivessel coronary artery disease: A systematic review and meta-analysis. Cardiovascular revascularization medicine : including molecular interventions. 2025 Jan. 38849266
  13. [13] Yadav B, Rai A et al.. Safety and efficacy of Ayurvedic interventions and Yoga on long term effects of COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021 Jun 3. 34082792
  14. [14] Cui K, Lyu S et al.. Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes. Cardiovascular diabetology. 2019 Sep 17. 31530274
  15. [15] Michailidis N, Pallikarou M et al.. Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine. Pharmacogenomics. 2026 Jan-Feb. 41906868
  16. [16] Dobesh PP, Finks SW et al.. Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. Clinical therapeutics. 2020 Oct. 32873416
  17. [17] Giugliano RP, Wiviott SD et al.. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA cardiology. 2017 May 1. 28291866
  18. [18] Weitz JI, Angiolillo DJ et al.. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and haemostasis. 2020 Aug. 32594508
  19. [19] Zhang RY, DU R et al.. Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation. Chinese medical journal. 2008 Dec 20. 19187586
  20. [20] Kim S, Park J et al.. Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency. Arteriosclerosis, thrombosis, and vascular biology. 2026 May. 41783931

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts